Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
pazopanib
i
Other names:
GW-786034, GW-786034B, SB-786034, GW 786034, GW 786034B, SB786034, SB 786034, GW786034, GW786034B, 786034
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(76)
News
Trials
Company:
Generic mfg.
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
›
Associations
(76)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
pazopanib
Sensitive: A1 - Approval
pazopanib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Uterine Corpus Leiomyosarcoma
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Kidney Cancer
No biomarker
Kidney Cancer
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
SDHB deletion
Gastrointestinal Stromal Tumor
SDHB deletion
Gastrointestinal Stromal Tumor
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
TFE3 fusion
Sarcoma
TFE3 fusion
Sarcoma
pazopanib
Sensitive: C2 – Inclusion Criteria
pazopanib
Sensitive
:
C2
pazopanib
Sensitive: C2 – Inclusion Criteria
pazopanib
Sensitive
:
C2
HDAC2 expression
Renal Cell Carcinoma
HDAC2 expression
Renal Cell Carcinoma
pazopanib + CG-781
Sensitive: C3 – Early Trials
pazopanib + CG-781
Sensitive
:
C3
pazopanib + CG-781
Sensitive: C3 – Early Trials
pazopanib + CG-781
Sensitive
:
C3
FLT4 T494A
Neuroendocrine Tumor
FLT4 T494A
Neuroendocrine Tumor
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
FLT4 R1324L
Neuroendocrine Tumor
FLT4 R1324L
Neuroendocrine Tumor
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
TP53 mutation
Neuroendocrine Tumor
TP53 mutation
Neuroendocrine Tumor
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
VEGFA elevation
Renal Cell Carcinoma
VEGFA elevation
Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
CXCL12 elevation
Renal Cell Carcinoma
CXCL12 elevation
Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
SPP1-L
Renal Cell Carcinoma
SPP1-L
Renal Cell Carcinoma
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
HGF-L
Renal Cell Carcinoma
HGF-L
Renal Cell Carcinoma
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
CXCL8-L
Renal Cell Carcinoma
CXCL8-L
Renal Cell Carcinoma
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
IL6-L
Renal Cell Carcinoma
IL6-L
Renal Cell Carcinoma
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
VHL mutation
Clear Cell Renal Cell Carcinoma
VHL mutation
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
VHL promoter methylation
Clear Cell Renal Cell Carcinoma
VHL promoter methylation
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
EPAS1 overexpression
Clear Cell Renal Cell Carcinoma
EPAS1 overexpression
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
HIF1A expression
Clear Cell Renal Cell Carcinoma
HIF1A expression
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
KDR elevation
Skin Cancer
KDR elevation
Skin Cancer
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
PD-L1 expression
Soft Tissue Sarcoma
PD-L1 expression
Soft Tissue Sarcoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
KDR C482R
Clear Cell Renal Cell Carcinoma
KDR C482R
Clear Cell Renal Cell Carcinoma
crizotinib + pazopanib
Sensitive: C3 – Early Trials
crizotinib + pazopanib
Sensitive
:
C3
crizotinib + pazopanib
Sensitive: C3 – Early Trials
crizotinib + pazopanib
Sensitive
:
C3
ALK R1209Q
Colon Cancer
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive: C3 – Early Trials
crizotinib + pazopanib
Sensitive
:
C3
crizotinib + pazopanib
Sensitive: C3 – Early Trials
crizotinib + pazopanib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login